Letters, Testimony & Comments

BIO’s Mission is to be the champion for biotechnology. We advocate for policies that will enable the realization of biotechnology’s promise for providing breakthrough products to cure disease, protecting against bio-terrorism, feeding the hungry, and cleaning our environment.

Representative Matt Hudson Florida House of Representatives 402 South Monroe Street Tallahassee, FL 32399 Dear Representative Hudson...
February 1 2013
Biologics are complex medicines manufactured from living organisms. Unlike traditional “small molecule” drugs, biologics are...
January 24 2013
The Biotechnology Industry Organization (BIO) is the world’s largest biotechnology trade association. BIO represents more than 1,...
January 24 2013
The Biotechnology Industry Organization (BIO) is the world’s largest biotechnology trade association. BIO represents more than 1,...
January 24 2013
In December 2012, Virginia House Delegate John M. O'Bannon, III introduced the Interchangeable biosimilar biological products bill (H...
January 10 2013
March 24, 2011 As our economy begins to improve, job creation remains a critical priority toward ensuring a broad, deep and sustained...
March 24 2011
Re: Microsoft Corp. v. i4i L.P. and Infrastructures for Information Inc., pending in the United States Supreme Court, No. 10-290...
January 13 2011
Dear President Obama: The organizations below urge your Administration to maintain robust funding levels for the Department of...
January 11 2011
Re: IPR and Technology discussions at Cancún Climate Change Talks Dear Secretary Clinton and Ambassador Stern: At this very...
December 7 2010
Dear Chairman Inouye and Ranking Member Cochran: As the Senate debates fiscal year 2011 federal funding, the undersigned organizations...
June 1 2010
May 8 2013
BIO  urges Florida Governor Scott to sign House Bill 365 – a bill related to the substitution of biologic and biosimilar medicines – which recently passed out of the Legislature.
February 1 2013
BIO supports passage of Florida House Bill 365, which provides requirements for pharmacist to dispense substitute biological products that are determined to be interchangeable for prescribed biological product.
January 24 2013
To ensure transparency and communication between patients and their treatment teams, BIO believes that certain safeguards should guide substitution policies for interchangeable biologics under state law as well.
January 24 2013
The policies outlined in Senate Bill 2190 align with all five of BIO’s Principles on Biologic Product Substitution and we therefore support its passage.
January 24 2013
BIO opposes the proposal to subject certain cancer therapies to prior authorization measures under Senate Bill 2066.
July 11 2014
Today's oral arguments offered an important opportunity to educate stakeholders within Alameda County and all of California about the unnecessary and burdensome impacts that will result if this proposed take back program is allowed to stand.
May 29 2014
Delaware Governor Markell signed legislation designed to create a pathway for the substitution of interchangeable biologic medicines.
March 25 2014
The Biotechnology Industry Organization (BIO) and the Indiana Health Industry Forum (IHIF) commend Indiana Governor Mike Pence for signing legislation today designed to create a pathway for the substitution of interchangeable biologic medicines.
January 22 2014
BIO and WBBA commend the Washington State House and Senate for continuing to advance legislation designed to create a pathway for the substitution of interchangeable biologic medicines.
November 13 2013
The Pennsylvania Senate Public Health and Welfare Committee approved Senate Bill 405, which would require a pharmacist to notify the patient and, within 72 hours, the patient’s physician of any biologic product substitution.